Glycopyrrolate NDC 72162-2598

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2598Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2598Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2598-1	72162259801	100 TABLET in 1 BOTTLE (72162-2598-1)Marketed from Jan 7, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Glycopyrrolate
Generic name (nonproprietary): glycopyrrolate
Active ingredients: Glycopyrrolate — 2 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212696
Marketing start: Oct 10, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Cholinergic Antagonists (Mechanism)Cholinergic Muscarinic Antagonists (Mechanism)
Identifiers: Product ID 72162-2598_b9bd5133-77c0-483b-b0f5-5ddf8edeaadbSPL ID b9bd5133-77c0-483b-b0f5-5ddf8edeaadbSPL set ID b96c54a1-b8a5-4132-ae6d-725e0e5b91f4RxCUI 197739UNII V92SO9WP2I
Pharmacologic class: Anticholinergic; Cholinergic Muscarinic Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162259801 followed by a unit qualifier and the quantity

Package 72162-2598-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 7, 2026.

Indications (excerpt from the label)

Glycopyrrolate tablets are indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. Limitations of Use Glycopyrrolate tablets are not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. Glycopyrrolate tablet are anticholinergics indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. (1) Limitations of Use: Not indicated as monotherapy for the treatment of peptic ulcer because effectiveness in peptic ulcer healing has not been established. (1)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212696

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212696
Product	Strength	Form · route	Labeler	Product NDC
Glycopyrrolate	Glycopyrrolate 1 mg/1	TabletOral	QUAGEN PHARMACEUTICALS LLC	70752-108
Glycopyrrolate	Glycopyrrolate 2 mg/1	TabletOral	QUAGEN PHARMACEUTICALS LLC	70752-109
Glycopyrrolate	Glycopyrrolate 2 mg/1	TabletOral	REMEDYREPACK INC.	70518-4537
Glycopyrrolate	Glycopyrrolate 1 mg/1	TabletOral	Bryant Ranch Prepack	72162-2597